review
focus
common
communityacquir
respiratori
virus
transmit
via
aerosol
droplet
direct
contact
patient
hematolog
malign
hm
hematopoiet
stem
cell
transplant
hsct
recipi
includ
influenza
viru
respiratori
syncyti
viru
rsv
parainfluenza
viru
piv
human
enteroviru
hev
human
rhinoviru
hrv
coronaviru
cov
human
metapneumoviru
hmpv
cytomegolaviru
cmv
also
includ
cmv
pneumonia
play
import
role
among
immunocompromis
patient
latent
endogen
virus
associ
viral
pneumonia
popul
less
preval
beyond
scope
articl
standard
definit
viral
pneumonia
accept
distinct
gener
made
viral
upper
respiratori
tract
infect
urti
lower
respiratori
tract
infect
lrti
viral
lrti
includ
viral
tracheiti
bronchiti
bronchiol
alveol
viral
pneumonia
typic
understood
describ
infecti
syndrom
symptom
consist
respiratori
infect
eg
cough
rhinorrhea
dyspnea
isol
viral
pathogen
known
caus
respiratori
infect
either
nasal
oropharyng
tracheal
bronchoalveolar
secret
new
infiltr
chest
xray
cxr
comput
tomographi
ct
patient
receiv
tcell
deplet
chemotherapeut
agent
eg
alemtuzumab
fludarabin
antithymocyt
globulin
appear
remain
elev
risk
treatment
case
year
treatment
complet
use
agent
appear
especi
import
risk
develop
cmv
diseas
hsct
recipi
furthermor
infect
virus
influenza
rsv
directli
impair
lymphocyt
function
previous
healthi
patient
even
moder
chemotherapyinduc
lymphopenia
andor
lymphocyt
dysfunct
may
place
hmhsct
patient
elev
risk
viral
pneumonia
larg
singl
center
studi
hsct
patient
acut
gvhd
develop
viral
pneumonia
compar
among
patient
without
gvhd
similar
find
describ
hsct
patient
develop
cmv
diseas
individu
respiratori
virus
cmv
pneumonia
princip
aris
diseas
reactiv
hsct
recipi
seroposit
cmv
r
prior
transplant
irrespect
donor
statu
highest
risk
reactiv
latent
viru
altern
seroneg
recipi
face
limit
reactiv
risk
rate
cmv
pneumonia
lower
r
recipi
even
seroposit
donor
addit
risk
factor
progress
viral
urti
viral
pneumonia
identifi
multivari
analys
includ
age
greater
year
hypoalbuminemia
cumul
dose
corticosteroid
exposur
virus
promin
driven
season
variat
viral
carriag
gener
influenza
rsv
hmpv
infect
peak
late
autumn
continu
winter
hrv
demonstr
biphas
peak
autumn
spring
parainfluenza
rate
highest
spring
summer
although
certain
subtyp
present
year
pandem
local
outbreak
increas
risk
viru
acquir
commun
household
contact
nosocomi
outbreak
also
result
signific
morbid
mortal
due
intens
exposur
healthcar
environ
coupl
diseaserel
suscept
viral
infect
care
molecular
type
viral
isol
demonstr
nosocomi
outbreak
persist
outpati
inpati
set
despit
establish
infect
control
practic
cough
andor
sore
throat
appli
patient
solid
organ
transplant
hsct
present
influenza
found
posit
predict
valu
neg
predict
valu
use
criteria
ferguson
colleagu
appli
clinic
predict
score
use
urti
lrti
symptom
hsct
recipi
found
posit
predict
valu
neg
predict
valu
studi
suggest
symptom
common
viral
infect
immunocompet
patient
moder
sensit
poorli
specif
patient
hmhsct
rsv
pneumonia
fever
cough
dyspnea
wheez
common
wherea
rhinorrhea
sore
throat
less
frequent
observ
larg
retrospect
studi
patient
hsct
piv
patient
present
upper
respiratori
tract
symptom
present
upper
lower
respiratori
tract
symptom
hrv
infect
usual
exacerb
symptom
associ
underli
chronic
lung
diseas
includ
dyspnea
chest
tight
wheez
hev
present
frequent
cough
even
lower
respiratori
involv
suspect
limit
inform
avail
hmpv
cough
wheez
fever
predomin
symptom
cmv
pneumonia
nonspecif
usual
consist
nonsuppur
pneumon
includ
nonproduct
cough
dyspnea
hypoxia
presenc
fever
variabl
sinc
cmv
pneumonia
may
also
coincid
cmv
viremia
symptom
fever
malais
arthralgia
cytopenia
elev
liver
associ
enzym
may
also
occur
patient
hmhsct
mani
potenti
caus
respiratori
symptom
pulmonari
infiltr
fever
thu
high
degre
suspicion
essenti
diagnos
viral
pneumonia
patient
nonspecif
symptom
clinician
must
remain
vigil
consider
patient
risk
factor
time
year
exposur
histori
suspect
viral
infect
promptli
refer
laboratori
radiograph
evalu
figur
present
algorithm
approach
patient
present
syndrom
suggest
viral
respiratori
infect
viral
nucleic
acid
amplif
techniqu
use
pcr
microarray
dna
chip
technolog
larg
supplant
direct
fluoresc
antibodi
dfa
stain
convent
viral
cultur
diagnosi
respiratori
virus
techniqu
specif
valid
patient
hmhsct
sampl
nucleic
acid
assay
commonli
obtain
nasopharynx
use
steril
swab
wash
similar
test
perform
observ
analyz
sputum
sampl
tracheal
aspir
bal
fluid
plain
cxr
demonstr
lower
respiratori
tract
involv
viral
infect
nonspecif
poor
neg
predict
valu
particularli
hmhsct
patient
studi
logan
et
al
radiologistinterpret
cxr
predict
correct
type
infect
immunocompromis
patient
pneumonia
time
forti
eight
percent
patient
whose
chest
ct
suggest
pneumonia
found
cxr
interpret
normal
shown
figur
ct
pattern
commonli
observ
viral
pneumonia
ground
glass
opac
ggo
nodul
interlobular
septal
thicken
bronchial
wall
thicken
subtl
chang
attenu
wide
presum
distinct
radiograph
pattern
relat
uniqu
histopatholog
injuri
caus
differ
virus
consider
histopatholog
radiograph
overlap
respiratori
virus
render
find
nonspecif
furthermor
patient
hmhsct
viral
pneumonia
frequent
coinfect
bacteri
fungal
pathogen
radiograph
pattern
may
confound
noninfecti
condit
influenza
viru
associ
bronchial
thicken
mucu
plug
termin
bronchiol
ggo
nodul
may
evolv
confluent
opac
sever
influenza
may
associ
secondari
infect
andor
acut
respiratori
distress
syndrom
potenti
present
consolid
opac
case
seri
adult
patient
hmhsct
rsv
pneumonia
common
pattern
centrilobular
subcentimet
nodul
airspac
consolid
ggo
bronchial
wall
thicken
piv
manifest
often
multipl
peribronchi
subcentimet
nodul
ggo
predomin
pattern
hmpv
mixtur
bilater
ggo
subcentimet
nodular
opac
without
predilect
lung
zone
littl
data
avail
hrv
viral
pneumonia
bilater
diffus
ggo
describ
cmv
may
present
milliari
pattern
diffus
interstiti
pneumon
ggo
small
centrilobular
nodul
air
space
opac
order
assess
progress
lower
respiratori
tract
detect
addit
pathogen
bal
frequent
recommend
hmhsct
patient
respiratori
symptom
identifi
viru
upper
respiratori
sampl
particularli
set
abnorm
cxr
ct
metaanalysi
bal
lung
biopsi
patient
cancer
hsct
demonstr
overal
yield
infecti
etiolog
bal
sampl
contain
identifi
viru
diagnost
yield
bal
reduc
substanti
hsct
patient
bronchoscopi
delay
day
present
infecti
caus
bal
diagnost
perform
cmv
pneumonia
depend
analyt
modal
chosen
shell
vial
cultur
high
sensit
poor
specif
diagnos
tissueinvas
diseas
cytolog
examin
demonstr
cmv
intracytoplasm
inclus
highli
specif
poorli
sensit
pcr
highli
sensit
specif
pretest
clinic
suspicion
cmv
pneumonia
high
patient
without
respiratori
symptom
pcr
base
result
may
result
falseposit
pulmonari
shed
viru
common
patient
cmv
infect
without
tissueinvas
diseas
theori
falseposit
could
mitig
quantit
pcr
techniqu
viral
dna
threshold
establish
prognost
valu
isol
viru
lower
respiratori
tract
bal
subject
recent
investig
seo
colleagu
found
hsct
patient
new
pulmonari
infiltr
baldetect
piv
wors
surviv
patient
new
infiltr
piv
detect
upper
respiratori
tract
vs
altern
studi
campbel
et
al
evalu
prognost
valu
quantit
pcr
bal
sampl
found
high
viral
copi
number
piv
predictor
outcom
role
lung
biopsi
either
surgic
endoscop
unclear
although
lung
biopsi
superior
bal
diagnos
noninfecti
lung
patholog
associ
signific
complic
procedurerel
mortal
high
clinic
suspicion
diagnosi
viral
pneumonia
would
need
justifi
tissu
biopsi
hmhsct
patient
new
pulmonari
infiltr
studi
hsct
recipi
resid
outpati
residenti
facil
undergo
treatment
oseltamivir
provid
resid
sever
patient
diagnos
influenza
initi
new
case
influenza
diagnos
durat
influenza
season
compar
favor
match
control
previou
year
human
monoclon
antibodi
palivizumab
pvz
effect
reduc
rate
rsv
transmiss
children
hsct
studi
kassi
et
al
children
hsct
inpati
ward
consid
high
risk
contract
rsv
outbreak
receiv
pzv
none
contract
rsv
chemoprophylaxi
cmv
recipi
hsct
critic
import
prevent
tissueinvas
diseas
prevent
strategi
multimod
focu
prevent
primari
cmv
infect
possibl
prevent
cmv
reactiv
seroposit
hsct
recipi
preemptiv
therapi
patient
earli
indic
cmv
reactiv
chemoprophylaxi
yet
avail
respiratori
viral
infect
given
unpredict
viru
exposur
pattern
profound
immun
defect
hmhsct
patient
narrow
specif
avail
chemoprev
agent
broad
stimul
antivir
respons
via
hostdirect
therapi
may
provid
opportun
enhanc
surviv
popul
number
group
focus
stimul
antivir
protect
manipul
pattern
recognit
receptor
two
class
antivir
agent
approv
treatment
influenza
proton
channel
inhibitor
amantadin
rimantadin
antivir
activ
influenza
viru
na
inhibitor
oseltamivir
oral
zanamivir
inhal
peramivir
intraven
activ
influenza
b
viru
given
high
level
resist
seri
report
inhibitor
influenza
cdc
recommend
empir
therapi
na
inhibitor
high
risk
patient
patient
hmhsct
consid
high
risk
na
inhibitor
start
without
delay
confirm
suspect
influenza
infect
confer
mortal
benefit
hm
hsct
inpati
outpati
set
studi
averag
durat
na
therapi
day
howev
optim
durat
unknown
patient
hmhsct
frequent
demonstr
prolong
viral
shed
aerosol
ribavirin
deliv
via
facemask
scaveng
tent
approv
treatment
rsv
infect
children
use
frequent
high
risk
adult
data
support
use
adult
hmhsct
mainli
retrospect
studi
demonstr
improv
mortal
reduct
progress
pneumonia
combin
therapi
ivig
pvz
also
seem
reduc
mortal
vakil
similarli
clearli
reduc
progress
pneumonia
durat
therapi
usual
day
may
longer
sever
diseas
aerosol
ribavirin
caus
bronchospasm
patient
asthma
chronic
obstruct
pulmonari
diseas
copd
also
associ
high
treatment
cost
especi
combin
ivig
pvz
compassion
use
ribavirin
ivig
patient
piv
hmpv
pneumonia
describ
mortal
benefit
reduct
rate
progress
pneumonia
demonstr
cmv
pneumonia
gener
treat
intraven
ganciclovir
foscarnet
combin
ivig
cmvspecif
immunoglobulin
cmvig
intens
induct
phase
follow
mainten
therapi
durat
treatment
depend
patient
risk
factor
viral
burden
respons
treatment
institut
prefer
gener
consid
first
line
agent
treatment
ganciclovir
limit
myelosuppress
consid
contraind
preengraft
phase
transplant
neutropen
patient
ganciclovir
resist
also
signific
concern
foscarnet
use
limit
nephrotox
combin
therapi
describ
cmvantigenemia
may
play
role
select
case
oral
valin
ester
valganciclovir
valacyclovir
recommend
random
trial
compar
antivir
therapi
without
immunoglobulin
avail
benefit
immunoglobulin
debat
howev
given
high
mortal
associ
cmv
pneumonia
limit
toxic
profil
ivg
cmvig
combin
therapi
favor
choic
immunoglobulin
base
cost
avail
institut
prefer
sever
novel
therapi
develop
varieti
respiratori
virus
hm
hsct
patient
tabl
present
annot
list
promis
antivir
therapi
rate
bacteri
fungal
viral
copathogen
infect
high
hmhsct
patient
viral
infect
exact
rate
difficult
estim
due
confound
element
relat
studi
identifi
prompt
treatment
copathogen
imper
patient
hmhsct
comorbid
underli
lung
diseas
particularli
asthma
copd
increas
risk
respiratori
failur
especi
hrv
infect
appropri
therapi
bronchospasm
airway
inflamm
part
treatment
algorithm
signific
heterogen
report
studi
mortal
caus
respiratori
viral
infect
hmhsct
patient
base
singlecent
experi
publish
mortal
rate
influenza
pneumonia
vari
depend
center
use
na
inhibitor
influenza
strain
data
larg
cancer
center
influenza
epidem
demonstr
mortal
influenza
pneumonia
hsct
patient
receiv
na
inhibitor
influenza
prophylaxi
prospect
data
sever
european
center
demonstr
allcaus
mortal
vakil
patient
hsct
influenza
studi
earli
initi
oseltamivir
hsct
patient
influenza
b
brazil
mortal
patient
studi
outbreak
prospect
survey
hsct
recipi
sever
european
center
report
attribut
mortal
mortal
rsv
pneumonia
high
rate
report
mortal
hrv
associ
pneumonia
commonli
associ
coinfect
overal
mortal
patient
piv
develop
pneumonia
two
larg
retrospect
studi
day
limit
data
avail
hmpv
mortal
rate
report
risk
mortal
hev
nonepidem
cov
appear
low
data
need
overal
mortal
cmvpneumon
patient
hsct
larg
transplant
center
respiratori
viru
infect
may
also
result
progress
loss
lung
function
particularli
patient
hsct
erard
et
al
retrospect
studi
patient
hsct
year
period
found
patient
develop
airflow
limit
improv
follow
resolut
infect
viral
infect
also
independ
associ
bronchiol
obliteran
syndrom
idiopath
pulmonari
syndrom
hsct
viral
infect
may
also
impact
graft
function
toupin
et
al
respiratori
virus
increasingli
recogn
caus
pneumonia
patient
hmhsct
associ
notabl
morbid
modern
molecular
diagnost
tool
coupl
high
index
suspicion
assist
identif
patient
viral
pneumonia
chest
radiograph
ct
scan
consid
patient
symptom
sign
lower
respiratori
tract
involv
referr
bronchoscopi
delay
prompt
empir
antivir
follow
tailor
therapi
administ
treatment
avail
care
manag
copathogen
comorbid
pulmonari
diseas
critic
patient
hmhsct
receiv
yearli
influenza
vaccin
patient
famili
healthcar
worker
routin
educ
hand
hygien
isol
practic
institut
polici
infect
control
strictli
enforc
much
remain
understudi
larg
prospect
studi
need
improv
understand
role
respiratori
viru
play
patient
hm
hsct
vakil
viral
pneumonia
patient
hematolog
malign
recipi
hematopoiet
stem
cell
transplantat
caus
signific
morbid
mortal
advanc
diagnost
techniqu
enabl
rapid
identif
respiratori
viral
pathogen
upper
lower
respiratori
tract
sampl
lymphopenia
myeloabl
tcell
deplet
chemotherapi
graftversu
host
diseas
factor
increas
risk
develop
lifethreaten
viral
pneumonia
chest
imag
often
nonspecif
may
aid
diagnos
bronchoscopi
bronchoalveolar
lavag
recommend
high
risk
viral
pneumonia
new
infiltr
chest
imag
earli
initi
antivir
therapi
patient
influenza
respiratori
syncyti
viru
recommend
investig
novel
prevent
therapeut
treatment
respiratori
pathogen
ongo
given
limit
current
treatment
option
emphasi
place
prevent
strict
adher
isol
protocol
vakil
